$LTRN
Lantern Pharma Inc.

2024 Q4 Form 10-Q Financial Statement

#000149315224044010 Filed on November 07, 2024

View on sec.gov

Income Statement

Concept 2024 Q4 2024 Q3
Revenue $0.00
YoY Change
Cost Of Revenue
YoY Change
Gross Profit
YoY Change
Gross Profit Margin
Selling, General & Admin $1.463M
YoY Change 11.67%
% of Gross Profit
Research & Development $3.717M
YoY Change 68.18%
% of Gross Profit
Depreciation & Amortization $4.390K
YoY Change
% of Gross Profit
Operating Expenses $5.180M
YoY Change 47.0%
Operating Profit -$5.180M
YoY Change 47.0%
Interest Expense $191.4K
YoY Change -23.46%
% of Operating Profit
Other Income/Expense, Net $482.5K
YoY Change 316.77%
Pretax Income -$4.506M
YoY Change 42.59%
Income Tax
% Of Pretax Income
Net Earnings -$4.506M
YoY Change 42.52%
Net Earnings / Revenue
Basic Earnings Per Share -$0.42
Diluted Earnings Per Share -$0.42
COMMON SHARES
Basic Shares Outstanding 10.78M shares 10.76M shares
Diluted Shares Outstanding 10.76M shares

Balance Sheet

Concept 2024 Q4 2024 Q3
SHORT-TERM ASSETS
Cash & Short-Term Investments $28.05M
YoY Change -37.56%
Cash & Equivalents $8.103M
Short-Term Investments $19.95M
Other Short-Term Assets $1.867M
YoY Change -25.31%
Inventory
Prepaid Expenses
Receivables
Other Receivables
Total Short-Term Assets $29.92M
YoY Change -36.91%
LONG-TERM ASSETS
Property, Plant & Equipment $48.93K
YoY Change -4.1%
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments
YoY Change
Other Assets $36.74K
YoY Change 42.02%
Total Long-Term Assets $372.3K
YoY Change 7.75%
TOTAL ASSETS
Total Short-Term Assets $29.92M
Total Long-Term Assets $372.3K
Total Assets $30.29M
YoY Change -36.59%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable $3.404M
YoY Change 62.86%
Accrued Expenses $197.3K
YoY Change 16.05%
Deferred Revenue
YoY Change
Short-Term Debt $0.00
YoY Change
Long-Term Debt Due
YoY Change
Total Short-Term Liabilities $3.601M
YoY Change 59.81%
LONG-TERM LIABILITIES
Long-Term Debt $0.00
YoY Change
Other Long-Term Liabilities $93.95K
YoY Change -14.59%
Total Long-Term Liabilities $93.95K
YoY Change -14.59%
TOTAL LIABILITIES
Total Short-Term Liabilities $3.601M
Total Long-Term Liabilities $93.95K
Total Liabilities $3.695M
YoY Change 56.58%
SHAREHOLDERS EQUITY
Retained Earnings -$70.15M
YoY Change 37.39%
Common Stock $1.078K
YoY Change -0.83%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity $26.60M
YoY Change
Total Liabilities & Shareholders Equity $30.29M
YoY Change -36.59%

Cashflow Statement

Concept 2024 Q4 2024 Q3
OPERATING ACTIVITIES
Net Income -$4.506M
YoY Change 42.52%
Depreciation, Depletion And Amortization $4.390K
YoY Change
Cash From Operating Activities -$5.582M
YoY Change 54.63%
INVESTING ACTIVITIES
Capital Expenditures $3.030K
YoY Change
Acquisitions
YoY Change
Other Investing Activities $683.4K
YoY Change 184.74%
Cash From Investing Activities $680.3K
YoY Change 195.8%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities 11.99K
YoY Change
NET CHANGE
Cash From Operating Activities -5.582M
Cash From Investing Activities 680.3K
Cash From Financing Activities 11.99K
Net Change In Cash -4.890M
YoY Change 44.67%
FREE CASH FLOW
Cash From Operating Activities -$5.582M
Capital Expenditures $3.030K
Free Cash Flow -$5.585M
YoY Change 54.72%

Facts In Submission

Frame Concept Type Concept / XBRL Key Value Unit
CY2024Q3 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
usd
CY2023Q4 us-gaap Preferred Stock Value
PreferredStockValue
usd
CY2024Q3 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.0001
CY2024Q3 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
25000000 shares
CY2024Q3 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.0001
CY2023Q4 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
usd
dei Document Type
DocumentType
10-Q
dei Document Quarterly Report
DocumentQuarterlyReport
true
dei Document Period End Date
DocumentPeriodEndDate
2024-09-30
dei Document Fiscal Year Focus
DocumentFiscalYearFocus
2024
dei Document Transition Report
DocumentTransitionReport
false
dei Entity Registrant Name
EntityRegistrantName
Lantern Pharma Inc.
dei Entity Incorporation State Country Code
EntityIncorporationStateCountryCode
DE
dei Entity Tax Identification Number
EntityTaxIdentificationNumber
46-3973463
dei Entity Address Address Line1
EntityAddressAddressLine1
1920 McKinney Avenue
dei Entity Address Address Line2
EntityAddressAddressLine2
7th Floor
dei Entity Ex Transition Period
EntityExTransitionPeriod
true
dei Entity Shell Company
EntityShellCompany
false
CY2024Q4 dei Entity Common Stock Shares Outstanding
EntityCommonStockSharesOutstanding
10784725 shares
dei Entity Listing Par Value Per Share
EntityListingParValuePerShare
0.0001
CY2024Q3 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
8102819 usd
CY2023Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
21937749 usd
CY2024Q3 us-gaap Marketable Securities Current
MarketableSecuritiesCurrent
19950946 usd
CY2023Q4 us-gaap Marketable Securities Current
MarketableSecuritiesCurrent
19364923 usd
CY2024Q3 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
1867195 usd
CY2023Q4 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
2038653 usd
CY2024Q3 us-gaap Assets Current
AssetsCurrent
29920960 usd
CY2023Q4 us-gaap Assets Current
AssetsCurrent
43341325 usd
CY2024Q3 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
48931 usd
CY2023Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
52127 usd
CY2024Q3 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
286635 usd
CY2023Q4 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
228295 usd
CY2024Q3 us-gaap Other Assets Noncurrent
OtherAssetsNoncurrent
36738 usd
CY2023Q4 us-gaap Other Assets Noncurrent
OtherAssetsNoncurrent
25869 usd
CY2024Q3 us-gaap Assets
Assets
30293264 usd
CY2023Q4 us-gaap Assets
Assets
43647616 usd
CY2024Q3 us-gaap Accounts Payable And Accrued Liabilities Current
AccountsPayableAndAccruedLiabilitiesCurrent
3403799 usd
CY2023Q4 us-gaap Accounts Payable And Accrued Liabilities Current
AccountsPayableAndAccruedLiabilitiesCurrent
2505211 usd
CY2024Q3 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
197291 usd
CY2023Q4 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
172975 usd
CY2024Q3 us-gaap Liabilities Current
LiabilitiesCurrent
3601090 usd
CY2023Q4 us-gaap Liabilities Current
LiabilitiesCurrent
2678186 usd
CY2024Q3 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
93953 usd
CY2023Q4 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
61496 usd
CY2024Q3 us-gaap Liabilities
Liabilities
3695043 usd
CY2023Q4 us-gaap Liabilities
Liabilities
2739682 usd
CY2024Q3 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
1000000 shares
CY2023Q4 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
1000000 shares
CY2023Q4 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.0001
CY2024Q3 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
0 shares
CY2024Q3 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
0 shares
CY2023Q4 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
0 shares
CY2023Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
25000000 shares
CY2023Q4 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.0001
CY2023Q4 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
10721192 shares
CY2023Q4 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
10721192 shares
CY2024Q3 us-gaap Common Stock Value
CommonStockValue
1078 usd
CY2023Q4 us-gaap Common Stock Value
CommonStockValue
1072 usd
CY2024Q3 us-gaap Additional Paid In Capital
AdditionalPaidInCapital
96772824 usd
CY2023Q4 us-gaap Additional Paid In Capital
AdditionalPaidInCapital
96258726 usd
CY2024Q3 us-gaap Accumulated Other Comprehensive Income Loss Net Of Tax
AccumulatedOtherComprehensiveIncomeLossNetOfTax
-25264 usd
CY2023Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-55244404 usd
CY2024Q3 us-gaap Stockholders Equity
StockholdersEquity
26598221 usd
CY2023Q4 us-gaap Stockholders Equity
StockholdersEquity
40907934 usd
CY2024Q3 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
30293264 usd
CY2023Q4 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
43647616 usd
CY2024Q3 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
1462930 usd
CY2023Q3 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
1313727 usd
us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
4463869 usd
us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
4679128 usd
CY2024Q3 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
3716646 usd
CY2023Q3 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
2209894 usd
us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
11856169 usd
us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
8321058 usd
us-gaap Operating Expenses
OperatingExpenses
16320038 usd
us-gaap Operating Expenses
OperatingExpenses
13000186 usd
CY2024Q3 us-gaap Operating Income Loss
OperatingIncomeLoss
-5179576 usd
CY2023Q3 us-gaap Operating Income Loss
OperatingIncomeLoss
-3523621 usd
us-gaap Operating Income Loss
OperatingIncomeLoss
-16320038 usd
us-gaap Operating Income Loss
OperatingIncomeLoss
-13000186 usd
CY2024Q3 us-gaap Interest Income Other
InterestIncomeOther
191352 usd
CY2023Q3 us-gaap Interest Income Other
InterestIncomeOther
246394 usd
us-gaap Interest Income Other
InterestIncomeOther
580962 usd
us-gaap Interest Income Other
InterestIncomeOther
497999 usd
CY2024Q3 us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
482527 usd
CY2023Q3 us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
115777 usd
us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
833063 usd
us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
726574 usd
CY2024Q3 us-gaap Net Income Loss
NetIncomeLoss
-4505697 usd
CY2023Q3 us-gaap Net Income Loss
NetIncomeLoss
-3161450 usd
us-gaap Net Income Loss
NetIncomeLoss
-14906013 usd
us-gaap Net Income Loss
NetIncomeLoss
-11775613 usd
CY2024Q3 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.42
CY2024Q3 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.42
CY2023Q3 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.29
CY2023Q3 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.29
us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-1.39
us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-1.08
us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-1.08
CY2024Q3 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
10763351 shares
CY2024Q3 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
10763351 shares
CY2023Q3 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
10857366 shares
CY2023Q3 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
10857366 shares
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
10755015 shares
us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
10755015 shares
CY2023Q3 us-gaap Net Income Loss
NetIncomeLoss
-3161450 usd
us-gaap Net Income Loss
NetIncomeLoss
-14906013 usd
us-gaap Net Income Loss
NetIncomeLoss
-11775613 usd
us-gaap Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
165540 usd
CY2024Q3 us-gaap Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax
OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax
-56736 usd
CY2023Q3 us-gaap Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax
OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax
42041 usd
us-gaap Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax
OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax
-26290 usd
us-gaap Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax
OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax
67054 usd
CY2024Q3 us-gaap Other Comprehensive Income Loss Net Of Tax
OtherComprehensiveIncomeLossNetOfTax
-18679 usd
CY2023Q3 us-gaap Other Comprehensive Income Loss Net Of Tax
OtherComprehensiveIncomeLossNetOfTax
123045 usd
us-gaap Other Comprehensive Income Loss Net Of Tax
OtherComprehensiveIncomeLossNetOfTax
82196 usd
us-gaap Other Comprehensive Income Loss Net Of Tax
OtherComprehensiveIncomeLossNetOfTax
232594 usd
CY2024Q3 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-4524376 usd
CY2023Q3 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-3038405 usd
us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-14823817 usd
us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-11543019 usd
CY2022Q4 us-gaap Stockholders Equity
StockholdersEquity
56038024 usd
CY2023Q1 us-gaap Adjustments To Additional Paid In Capital Share Based Compensation Stock Options Requisite Service Period Recognition
AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition
333530 usd
CY2023Q1 us-gaap Net Income Loss
NetIncomeLoss
-3867765 usd
CY2023Q1 us-gaap Other Comprehensive Income Loss Net Of Tax
OtherComprehensiveIncomeLossNetOfTax
71709 usd
CY2023Q1 us-gaap Stockholders Equity
StockholdersEquity
52575498 usd
dei Amendment Flag
AmendmentFlag
false
dei Document Fiscal Period Focus
DocumentFiscalPeriodFocus
Q3
dei Current Fiscal Year End Date
CurrentFiscalYearEndDate
--12-31
dei Entity Central Index Key
EntityCentralIndexKey
0001763950
CY2024Q3 us-gaap Preferred Stock Value
PreferredStockValue
usd
CY2023Q2 us-gaap Stock Issued During Period Value Restricted Stock Award Gross
StockIssuedDuringPeriodValueRestrictedStockAwardGross
usd
CY2024Q3 us-gaap Stock Issued During Period Value Restricted Stock Award Gross
StockIssuedDuringPeriodValueRestrictedStockAwardGross
usd
us-gaap Proceeds From Warrant Exercises
ProceedsFromWarrantExercises
usd
us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
usd
LTRN Remeasurement Of Operating Lease Rightofuse Asset And Operating Lease Liability
RemeasurementOfOperatingLeaseRightofuseAssetAndOperatingLeaseLiability
usd
LTRN Removal Of Operating Lease Rightofuse Assets And Related Operating Lease Liabilities Upon Early Termination Of Leases
RemovalOfOperatingLeaseRightofuseAssetsAndRelatedOperatingLeaseLiabilitiesUponEarlyTerminationOfLeases
usd
CY2023Q2 us-gaap Lessee Operating Lease Renewal Term
LesseeOperatingLeaseRenewalTerm
P2Y
dei Entity File Number
EntityFileNumber
001-39318
dei Entity Address City Or Town
EntityAddressCityOrTown
Dallas
dei Entity Address State Or Province
EntityAddressStateOrProvince
TX
dei Entity Address Postal Zip Code
EntityAddressPostalZipCode
75201
dei City Area Code
CityAreaCode
(972)
dei Local Phone Number
LocalPhoneNumber
277-1136
dei Security12b Title
Security12bTitle
Common Stock, $0.0001 par value
dei Trading Symbol
TradingSymbol
LTRN
dei Security Exchange Name
SecurityExchangeName
NASDAQ
dei Entity Current Reporting Status
EntityCurrentReportingStatus
Yes
dei Entity Interactive Data Current
EntityInteractiveDataCurrent
Yes
dei Entity Filer Category
EntityFilerCategory
Non-accelerated Filer
dei Entity Small Business
EntitySmallBusiness
true
dei Entity Emerging Growth Company
EntityEmergingGrowthCompany
true
CY2023Q4 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
0 shares
CY2024Q3 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
10784725 shares
CY2024Q3 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
10784725 shares
CY2023Q4 us-gaap Accumulated Other Comprehensive Income Loss Net Of Tax
AccumulatedOtherComprehensiveIncomeLossNetOfTax
-107460 usd
CY2024Q3 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-70150417 usd
CY2024Q3 us-gaap Operating Expenses
OperatingExpenses
5179576 usd
CY2023Q3 us-gaap Operating Expenses
OperatingExpenses
3523621 usd
us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-1.39
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
10857150 shares
us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
10857150 shares
CY2024Q3 us-gaap Net Income Loss
NetIncomeLoss
-4505697 usd
CY2024Q3 us-gaap Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
38057 usd
CY2023Q3 us-gaap Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
81004 usd
us-gaap Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
108486 usd
CY2023Q2 us-gaap Adjustments To Additional Paid In Capital Share Based Compensation Stock Options Requisite Service Period Recognition
AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition
392390 usd
CY2023Q2 us-gaap Net Income Loss
NetIncomeLoss
-4746398 usd
CY2023Q2 us-gaap Other Comprehensive Income Loss Net Of Tax
OtherComprehensiveIncomeLossNetOfTax
37840 usd
CY2023Q2 us-gaap Stockholders Equity
StockholdersEquity
48259330 usd
CY2023Q3 us-gaap Adjustments To Additional Paid In Capital Share Based Compensation Stock Options Requisite Service Period Recognition
AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition
190755 usd
CY2023Q3 us-gaap Net Income Loss
NetIncomeLoss
-3161450 usd
CY2023Q3 us-gaap Other Comprehensive Income Loss Net Of Tax
OtherComprehensiveIncomeLossNetOfTax
123045 usd
CY2023Q3 us-gaap Stockholders Equity
StockholdersEquity
45411680 usd
CY2023Q4 us-gaap Stockholders Equity
StockholdersEquity
40907934 usd
CY2024Q1 us-gaap Stock Issued During Period Value New Issues
StockIssuedDuringPeriodValueNewIssues
54716 usd
CY2024Q1 us-gaap Adjustments To Additional Paid In Capital Share Based Compensation Stock Options Requisite Service Period Recognition
AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition
134057 usd
CY2024Q1 us-gaap Net Income Loss
NetIncomeLoss
-5440810 usd
CY2024Q1 us-gaap Other Comprehensive Income Loss Net Of Tax
OtherComprehensiveIncomeLossNetOfTax
109320 usd
CY2024Q1 us-gaap Stockholders Equity
StockholdersEquity
35765217 usd
CY2024Q2 us-gaap Adjustments To Additional Paid In Capital Share Based Compensation Stock Options Requisite Service Period Recognition
AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition
134171 usd
CY2024Q2 us-gaap Net Income Loss
NetIncomeLoss
-4959506 usd
CY2024Q2 us-gaap Other Comprehensive Income Loss Net Of Tax
OtherComprehensiveIncomeLossNetOfTax
-8445 usd
CY2024Q2 us-gaap Stockholders Equity
StockholdersEquity
30931437 usd
CY2024Q2 us-gaap Stockholders Equity
StockholdersEquity
30931437 usd
CY2024Q3 us-gaap Adjustments To Additional Paid In Capital Share Based Compensation Stock Options Requisite Service Period Recognition
AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition
179166 usd
CY2024Q3 us-gaap Stock Issued During Period Value New Issues
StockIssuedDuringPeriodValueNewIssues
11994 usd
CY2024Q3 us-gaap Net Income Loss
NetIncomeLoss
-4505697 usd
CY2024Q3 us-gaap Other Comprehensive Income Loss Net Of Tax
OtherComprehensiveIncomeLossNetOfTax
-18679 usd
CY2024Q3 us-gaap Other Comprehensive Income Loss Net Of Tax
OtherComprehensiveIncomeLossNetOfTax
-18679 usd
CY2024Q3 us-gaap Stockholders Equity
StockholdersEquity
26598221 usd
CY2024Q3 us-gaap Stockholders Equity
StockholdersEquity
26598221 usd
us-gaap Net Income Loss
NetIncomeLoss
-14906013 usd
us-gaap Net Income Loss
NetIncomeLoss
-11775613 usd
us-gaap Depreciation And Amortization
DepreciationAndAmortization
12708 usd
us-gaap Depreciation And Amortization
DepreciationAndAmortization
10640 usd
us-gaap Other Noncash Expense
OtherNoncashExpense
126561 usd
us-gaap Other Noncash Expense
OtherNoncashExpense
119886 usd
us-gaap Share Based Compensation
ShareBasedCompensation
447394 usd
us-gaap Share Based Compensation
ShareBasedCompensation
916675 usd
us-gaap Investment Income Net Amortization Of Discount And Premium
InvestmentIncomeNetAmortizationOfDiscountAndPremium
179673 usd
us-gaap Investment Income Net Amortization Of Discount And Premium
InvestmentIncomeNetAmortizationOfDiscountAndPremium
115395 usd
us-gaap Foreign Currency Transaction Gain Loss Before Tax
ForeignCurrencyTransactionGainLossBeforeTax
27746 usd
us-gaap Foreign Currency Transaction Gain Loss Before Tax
ForeignCurrencyTransactionGainLossBeforeTax
-129686 usd
us-gaap Debt Securities Available For Sale Realized Gain Loss
DebtSecuritiesAvailableForSaleRealizedGainLoss
8366 usd
us-gaap Debt Securities Available For Sale Realized Gain Loss
DebtSecuritiesAvailableForSaleRealizedGainLoss
-76820 usd
us-gaap Unrealized Gain Loss On Investments
UnrealizedGainLossOnInvestments
221124 usd
us-gaap Unrealized Gain Loss On Investments
UnrealizedGainLossOnInvestments
-17300 usd
us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
-155282 usd
us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
-442076 usd
us-gaap Increase Decrease In Accounts Payable And Accrued Liabilities
IncreaseDecreaseInAccountsPayableAndAccruedLiabilities
898560 usd
us-gaap Increase Decrease In Accounts Payable And Accrued Liabilities
IncreaseDecreaseInAccountsPayableAndAccruedLiabilities
-656096 usd
us-gaap Increase Decrease In Operating Lease Liability
IncreaseDecreaseInOperatingLeaseLiability
-128128 usd
us-gaap Increase Decrease In Operating Lease Liability
IncreaseDecreaseInOperatingLeaseLiability
-119197 usd
us-gaap Increase Decrease In Other Operating Assets
IncreaseDecreaseInOtherOperatingAssets
10869 usd
us-gaap Increase Decrease In Other Operating Assets
IncreaseDecreaseInOtherOperatingAssets
7980 usd
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-13841414 usd
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-10961198 usd
us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
9512 usd
us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
13653 usd
us-gaap Payments To Acquire Marketable Securities
PaymentsToAcquireMarketableSecurities
17476707 usd
us-gaap Payments To Acquire Marketable Securities
PaymentsToAcquireMarketableSecurities
6640738 usd
us-gaap Proceeds From Sale And Maturity Of Marketable Securities
ProceedsFromSaleAndMaturityOfMarketableSecurities
17408333 usd
us-gaap Proceeds From Sale And Maturity Of Marketable Securities
ProceedsFromSaleAndMaturityOfMarketableSecurities
5468000 usd
us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
-77886 usd
us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
-1186391 usd
us-gaap Proceeds From Warrant Exercises
ProceedsFromWarrantExercises
66710 usd
us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
66710 usd
us-gaap Effect Of Exchange Rate On Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
17660 usd
us-gaap Effect Of Exchange Rate On Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
-23649 usd
us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
-13834930 usd
us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
-12171238 usd
CY2023Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
21937749 usd
CY2022Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
37742966 usd
CY2024Q3 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
8102819 usd
CY2023Q3 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
25571728 usd
us-gaap Right Of Use Asset Obtained In Exchange For Operating Lease Liability
RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability
348623 usd
us-gaap Right Of Use Asset Obtained In Exchange For Operating Lease Liability
RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability
141989 usd
LTRN Remeasurement Of Operating Lease Rightofuse Asset And Operating Lease Liability
RemeasurementOfOperatingLeaseRightofuseAssetAndOperatingLeaseLiability
198847 usd
LTRN Removal Of Operating Lease Rightofuse Assets And Related Operating Lease Liabilities Upon Early Termination Of Leases
RemovalOfOperatingLeaseRightofuseAssetsAndRelatedOperatingLeaseLiabilitiesUponEarlyTerminationOfLeases
163722 usd
us-gaap Debt Securities Unrealized Gain Loss
DebtSecuritiesUnrealizedGainLoss
108486 usd
us-gaap Debt Securities Unrealized Gain Loss
DebtSecuritiesUnrealizedGainLoss
165540 usd
us-gaap Net Income Loss
NetIncomeLoss
-14906000 usd
us-gaap Net Income Loss
NetIncomeLoss
-11776000 usd
CY2024Q3 LTRN Working Capital
WorkingCapital
26320000 usd
us-gaap Use Of Estimates
UseOfEstimates
<p id="xdx_84B_eus-gaap--UseOfEstimates_zSKloZXnLXki" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="xdx_867_z1p4qQt1DDta">Use of Estimates and Assumptions</span></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The preparation of financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the reporting period. The significant areas of estimation include determining research and development accruals, the inputs in determining the fair value of equity-based awards and warrants issued, the inputs in determining present value of lease payments, and determining the fair value of marketable securities. Actual results could differ from those estimates.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p>
us-gaap Concentration Risk Credit Risk
ConcentrationRiskCreditRisk
<p id="xdx_84D_eus-gaap--ConcentrationRiskCreditRisk_z7v96aaYOhra" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="xdx_861_z2aJajq8S5g1">Risks and Uncertainties</span></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The Company operates in an industry that is subject to intense competition, government regulation and rapid technological change. Operations are subject to significant risk and uncertainties including financial, operational, technological, regulatory, and other risks, including the potential risk of business failure.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our marketable securities have had and may in the future have their market value fluctuate due to rises or falls in interest rates. While we believe our cash, cash equivalents and marketable securities do not contain excessive risk, we cannot provide absolute assurance that in the future our investments will not be subject to adverse changes in market value. In addition, we maintain significant amounts of cash and cash equivalents at one or more financial institutions that are federally insured. Interest bearing and non-interest bearing accounts we hold at these banking institutions are guaranteed by the Federal Deposit Insurance Corporation (“FDIC”) up to $<span id="xdx_906_eus-gaap--CashFDICInsuredAmount_iI_c20240930__srt--RangeAxis__srt--MaximumMember_z2zMElX9jTh8" title="Cash FDIC insured amount">250,000</span> per depositor, per FDIC-insured bank, per ownership category. Substantially all of our cash balances held at banking institutions at September 30, 2024 are in excess of FDIC coverage.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b> </b></span></p>
CY2024Q3 us-gaap Cash Equivalents At Carrying Value
CashEquivalentsAtCarryingValue
6970000 usd
CY2023Q4 us-gaap Cash Equivalents At Carrying Value
CashEquivalentsAtCarryingValue
20881000 usd
us-gaap Fair Value Adjustment Of Warrants
FairValueAdjustmentOfWarrants
103000 usd
CY2024Q3 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
286635 usd
CY2023Q4 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
228295 usd
CY2024Q3 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
197291 usd
CY2023Q4 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
172975 usd
CY2024Q3 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
93953 usd
CY2023Q4 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
61496 usd
CY2024Q3 us-gaap Operating Lease Liability
OperatingLeaseLiability
291244 usd
CY2023Q4 us-gaap Operating Lease Liability
OperatingLeaseLiability
234471 usd
CY2024Q3 us-gaap Lessee Operating Lease Liability Payments Remainder Of Fiscal Year
LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear
54129 usd
CY2024Q3 us-gaap Lessee Operating Lease Liability Payments Due Next Twelve Months
LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths
205315 usd
CY2024Q3 us-gaap Lessee Operating Lease Liability Payments Due Year Two
LesseeOperatingLeaseLiabilityPaymentsDueYearTwo
54744 usd
CY2024Q3 us-gaap Lessee Operating Lease Liability Payments Due
LesseeOperatingLeaseLiabilityPaymentsDue
314188 usd
CY2024Q3 us-gaap Lessee Operating Lease Liability Undiscounted Excess Amount
LesseeOperatingLeaseLiabilityUndiscountedExcessAmount
22944 usd
CY2024Q3 us-gaap Operating Lease Liability
OperatingLeaseLiability
291244 usd
CY2024Q3 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
197291 usd
CY2024Q3 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
93953 usd
CY2024Q2 us-gaap Short Term Lease Payments
ShortTermLeasePayments
11200 usd
CY2024Q3 us-gaap Short Term Lease Payments
ShortTermLeasePayments
6800 usd
CY2023Q4 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
228295 usd
CY2023Q4 us-gaap Operating Lease Liability
OperatingLeaseLiability
234471 usd
LTRN Operating Lease Rightofuse Asset Acquired
OperatingLeaseRightofuseAssetAcquired
348623 usd
LTRN Operating Lease Liability Acquired
OperatingLeaseLiabilityAcquired
348623 usd
LTRN Operating Lease Assets Early Termination
OperatingLeaseAssetsEarlyTermination
163722 usd
LTRN Operating Lease Liability Early Termination
OperatingLeaseLiabilityEarlyTermination
163722 usd
us-gaap Operating Lease Right Of Use Asset Amortization Expense
OperatingLeaseRightOfUseAssetAmortizationExpense
126561 usd
LTRN Operating Lease Liability Amortization Expense
OperatingLeaseLiabilityAmortizationExpense
128128 usd
CY2024Q3 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
286635 usd
CY2024Q3 us-gaap Operating Lease Liability
OperatingLeaseLiability
291244 usd
CY2024Q3 us-gaap Operating Lease Weighted Average Remaining Lease Term1
OperatingLeaseWeightedAverageRemainingLeaseTerm1
P1Y6M14D
CY2023Q3 us-gaap Operating Lease Weighted Average Remaining Lease Term1
OperatingLeaseWeightedAverageRemainingLeaseTerm1
P1Y6M29D
CY2024Q3 us-gaap Operating Lease Weighted Average Discount Rate Percent
OperatingLeaseWeightedAverageDiscountRatePercent
0.0950 pure
CY2023Q3 us-gaap Operating Lease Weighted Average Discount Rate Percent
OperatingLeaseWeightedAverageDiscountRatePercent
0.0736 pure
CY2024Q3 us-gaap Operating Lease Cost
OperatingLeaseCost
48300 usd
CY2023Q3 us-gaap Operating Lease Cost
OperatingLeaseCost
45000 usd
us-gaap Operating Lease Cost
OperatingLeaseCost
138300 usd
us-gaap Operating Lease Cost
OperatingLeaseCost
154000 usd
CY2024Q3 us-gaap Short Term Lease Cost
ShortTermLeaseCost
4800 usd
CY2023Q3 us-gaap Short Term Lease Cost
ShortTermLeaseCost
4000 usd
us-gaap Short Term Lease Cost
ShortTermLeaseCost
14100 usd
us-gaap Short Term Lease Cost
ShortTermLeaseCost
9000 usd
CY2024Q3 us-gaap Lease Cost
LeaseCost
53100 usd
CY2023Q3 us-gaap Lease Cost
LeaseCost
49000 usd
us-gaap Lease Cost
LeaseCost
152400 usd
us-gaap Lease Cost
LeaseCost
163000 usd
us-gaap Operating Lease Payments
OperatingLeasePayments
140000 usd
us-gaap Operating Lease Payments
OperatingLeasePayments
156000 usd
CY2024Q3 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
25000000 shares
CY2023Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
25000000 shares
CY2024Q3 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
10784725 shares
CY2024Q3 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
10784725 shares
CY2023Q4 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
10721192 shares
CY2023Q4 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
10721192 shares
CY2024Q3 us-gaap Class Of Warrant Or Right Number Of Securities Called By Warrants Or Rights
ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights
86685 shares
CY2023Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
1091196 shares
CY2023Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
6.11
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
241000 shares
us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice
4.63
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures And Expirations In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod
57650 shares
us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Expirations In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice
5.97
CY2024Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
1274546 shares
CY2024Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
5.83
CY2024Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber
960785 shares
CY2024Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice
6.20
CY2024Q3 us-gaap Share Based Compensation
ShareBasedCompensation
179166 usd
CY2023Q3 us-gaap Share Based Compensation
ShareBasedCompensation
190755 usd
us-gaap Share Based Compensation
ShareBasedCompensation
447394 usd
us-gaap Share Based Compensation
ShareBasedCompensation
916675 usd
CY2024Q3 LTRN Available For Sale Securities Amortized Costs
AvailableForSaleSecuritiesAmortizedCosts
20174127 usd
CY2024Q3 LTRN Marketable Securities Unrealized Gains
MarketableSecuritiesUnrealizedGains
116222 usd
CY2024Q3 LTRN Marketable Securities Unrealized Losses
MarketableSecuritiesUnrealizedLosses
339403 usd
CY2024Q3 us-gaap Marketable Securities Current
MarketableSecuritiesCurrent
19950946 usd
CY2024Q3 us-gaap Available For Sale Securities Debt Maturities Next Rolling Twelve Months Fair Value
AvailableForSaleSecuritiesDebtMaturitiesNextRollingTwelveMonthsFairValue
14157373 usd
CY2024Q3 LTRN Debt Securities Available For Sale Fair Value Position Less Than12 Months Accumulated Loss
DebtSecuritiesAvailableForSaleFairValuePositionLessThan12MonthsAccumulatedLoss
792134 usd
CY2024Q3 us-gaap Debt Securities Available For Sale Continuous Unrealized Loss Position Less Than12 Months Accumulated Loss
DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss
322 usd
CY2024Q3 LTRN Debt Securities Available For Sale Continuous Fair Value Position12 Months Or Longer Accumulated Loss
DebtSecuritiesAvailableForSaleContinuousFairValuePosition12MonthsOrLongerAccumulatedLoss
7522753 usd
CY2024Q3 us-gaap Debt Securities Available For Sale Continuous Unrealized Loss Position12 Months Or Longer Accumulated Loss
DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss
339081 usd
us-gaap Fair Value Measurement With Unobservable Inputs Reconciliation Recurring Basis Asset Transfers Net
FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetTransfersNet
25236352 usd
us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
1364546 shares
us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
1244706 shares

Files In Submission

Name View Source Status
0001493152-24-044010-index-headers.html Edgar Link pending
0001493152-24-044010-index.html Edgar Link pending
0001493152-24-044010.txt Edgar Link pending
0001493152-24-044010-xbrl.zip Edgar Link pending
ex31-1.htm Edgar Link pending
ex31-2.htm Edgar Link pending
ex32-1.htm Edgar Link pending
ex32-2.htm Edgar Link pending
Financial_Report.xlsx Edgar Link pending
form10-q.htm Edgar Link pending
ltrn-20240930.xsd Edgar Link pending
MetaLinks.json Edgar Link pending
R1.htm Edgar Link pending
R10.htm Edgar Link pending
R11.htm Edgar Link pending
R12.htm Edgar Link pending
R13.htm Edgar Link pending
R14.htm Edgar Link pending
R15.htm Edgar Link pending
R16.htm Edgar Link pending
R17.htm Edgar Link pending
R18.htm Edgar Link pending
R19.htm Edgar Link pending
R2.htm Edgar Link pending
R20.htm Edgar Link pending
R21.htm Edgar Link pending
R22.htm Edgar Link pending
R23.htm Edgar Link pending
R24.htm Edgar Link pending
R25.htm Edgar Link pending
R26.htm Edgar Link pending
R27.htm Edgar Link pending
R28.htm Edgar Link pending
R29.htm Edgar Link pending
R3.htm Edgar Link pending
R30.htm Edgar Link pending
R31.htm Edgar Link pending
R32.htm Edgar Link pending
R33.htm Edgar Link pending
R34.htm Edgar Link pending
R35.htm Edgar Link pending
R36.htm Edgar Link pending
R37.htm Edgar Link pending
R38.htm Edgar Link pending
R39.htm Edgar Link pending
R4.htm Edgar Link pending
ltrn-20240930_cal.xml Edgar Link unprocessable
ltrn-20240930_def.xml Edgar Link unprocessable
ltrn-20240930_lab.xml Edgar Link unprocessable
ltrn-20240930_pre.xml Edgar Link unprocessable
form10-q_htm.xml Edgar Link completed
R40.htm Edgar Link pending
R41.htm Edgar Link pending
R42.htm Edgar Link pending
R5.htm Edgar Link pending
R6.htm Edgar Link pending
R7.htm Edgar Link pending
R8.htm Edgar Link pending
R9.htm Edgar Link pending
report.css Edgar Link pending
Show.js Edgar Link pending
FilingSummary.xml Edgar Link unprocessable